Sector
PharmaceuticalsOpen
₹784.1Prev. Close
₹782.9Turnover(Lac.)
₹356.99Day's High
₹802.05Day's Low
₹76052 Week's High
₹1,997.452 Week's Low
₹761.1Book Value
₹242.19Face Value
₹10Mkt Cap (₹ Cr.)
4,050.43P/E
35.53EPS
22.05Divi. Yield
0The inspection raised, seven minor observations none related to data integrity, and therefore, the facility remains compliant under stringent regulatory standards.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 119.28 | 109.38 | 109.38 | 109.38 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,099.04 | 622.59 | 568.58 | 571.96 |
Net Worth | 1,218.32 | 731.97 | 677.96 | 681.34 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 556.97 | 450.69 | 505.44 | 644.16 |
yoy growth (%) | 23.58 | -10.83 | -21.53 | -14.71 |
Raw materials | -314.07 | -229.27 | -240.23 | -330.86 |
As % of sales | 56.38 | 50.87 | 47.52 | 51.36 |
Employee costs | -60.2 | -64.39 | -81.48 | -82.39 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | -52.77 | -95.87 | -149.83 | -401.47 |
Depreciation | -87.02 | -108.89 | -125.9 | -133.29 |
Tax paid | 0 | 0 | 0 | 46.19 |
Working capital | -202.58 | -42.4 | 475.45 | -144.74 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 23.58 | -10.83 | -21.53 | -14.71 |
Op profit growth | -1.1 | -230.8 | -425.39 | -703.41 |
EBIT growth | -53.38 | -69.42 | 45.93 | -12.7 |
Net profit growth | -95.89 | -21.81 | -57.82 | -27.27 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 819.37 | 665.9 | 559.56 | 450.06 | 483.81 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 819.37 | 665.9 | 559.56 | 450.06 | 483.81 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 30.86 | 58.64 | 67.47 | 15.23 | 24.28 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
Tanu Singla
Independent Director
Manoj Goyal
Managing Director
Manish Dhanuka
Whole-time Director
Mridul Dhanuka
Chairman (Non-Executive)
Ram Gopal Agarwal
Non Executive Director
Arjun Dhanuka
Independent Director
Dharam Vir
Independent Director
Shubha Singh
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Orchid Pharma Ltd
Summary
Orchid Pharma Limited, is one of the leading pharmaceutical companies in India head quartered in Chennai and involved in development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals with exports spanning over 40 countries. Orchids world class manufacturing infrastructure include USFDA compliant API and Finished Dosage Form facilities at Chennai in India. The Company has dedicated state-of-art and GLP compliant R&D infrastructure for Process Research, Drug Discovery and Pharmaceutical Research at Chennai. The Company has a portfolio of antibiotics, and veterinary products. Antibiotics are life-saving drugs used to ght infections. Different classes of antibiotics include Beta-lactam, Macrolide, Fluoroquinolone, Imidazoleetc. Cephalosporins are beta-lactam antimicrobials used to manage various infections from gram-positive and gramnegative bacteria. The ve generations of cephalosporins are useful against skin infections, urinary tract infections, lower respiratory tract infections, sexually transmitted diseases, surgical prophylaxis, and other infections like meningitis. Company is also engaged in manufacturing and export of general category nished dosage formulations and anti-infective nished dosage formulations through its formulation facilities.The Company is a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms
Read More
The Orchid Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹798.6 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Orchid Pharma Ltd is ₹4050.43 Cr. as of 02 Apr ‘25
The PE and PB ratios of Orchid Pharma Ltd is 35.53 and 3.13 as of 02 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Orchid Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Orchid Pharma Ltd is ₹761.1 and ₹1997.4 as of 02 Apr ‘25
Orchid Pharma Ltd's CAGR for 5 Years at 112.66%, 3 Years at 37.76%, 1 Year at -29.24%, 6 Month at -41.34%, 3 Month at -57.35% and 1 Month at -15.02%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.